Universal Beteiligungs und Servicegesellschaft mbH Makes New Investment in Viridian Therapeutics, Inc. $VRDN

Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 38,854 shares of the company’s stock, valued at approximately $1,209,000.

Other institutional investors have also made changes to their positions in the company. Hudson Bay Capital Management LP increased its stake in shares of Viridian Therapeutics by 46.6% in the third quarter. Hudson Bay Capital Management LP now owns 175,251 shares of the company’s stock worth $3,782,000 after purchasing an additional 55,689 shares during the period. Fisher Asset Management LLC increased its stake in shares of Viridian Therapeutics by 135.6% in the third quarter. Fisher Asset Management LLC now owns 1,201,226 shares of the company’s stock worth $25,922,000 after purchasing an additional 691,267 shares during the period. Propel Bio Management LLC bought a new position in shares of Viridian Therapeutics in the third quarter worth about $1,942,000. Y Intercept Hong Kong Ltd increased its stake in shares of Viridian Therapeutics by 430.3% in the third quarter. Y Intercept Hong Kong Ltd now owns 64,594 shares of the company’s stock worth $1,394,000 after purchasing an additional 52,414 shares during the period. Finally, SG Americas Securities LLC increased its stake in Viridian Therapeutics by 411.8% during the third quarter. SG Americas Securities LLC now owns 62,118 shares of the company’s stock valued at $1,341,000 after acquiring an additional 49,981 shares during the period.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. UBS Group assumed coverage on Viridian Therapeutics in a research note on Wednesday, January 7th. They set a “buy” rating and a $50.00 price target on the stock. Evercore restated an “outperform” rating and set a $44.00 price target on shares of Viridian Therapeutics in a research note on Tuesday, January 20th. Wells Fargo & Company lowered their price target on Viridian Therapeutics from $29.00 to $20.00 and set an “equal weight” rating on the stock in a research note on Tuesday, March 31st. Wedbush lowered their price target on Viridian Therapeutics from $37.00 to $31.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 8th. Finally, Needham & Company LLC lowered their price target on Viridian Therapeutics from $42.00 to $32.00 and set a “buy” rating on the stock in a research note on Monday, March 30th. Thirteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $37.07.

Viridian Therapeutics Trading Down 0.4%

VRDN stock opened at $13.42 on Friday. Viridian Therapeutics, Inc. has a 1-year low of $11.76 and a 1-year high of $34.29. The firm has a market cap of $1.38 billion, a P/E ratio of -4.08 and a beta of 0.82. The business’s 50 day moving average is $22.20 and its 200-day moving average is $27.01. The company has a current ratio of 12.65, a quick ratio of 12.65 and a debt-to-equity ratio of 0.08.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings data on Thursday, February 26th. The company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.18). Viridian Therapeutics had a negative net margin of 483.57% and a negative return on equity of 83.25%. The company had revenue of $0.13 million during the quarter, compared to the consensus estimate of $15.75 million. Equities analysts anticipate that Viridian Therapeutics, Inc. will post -3.79 earnings per share for the current fiscal year.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.